Literature DB >> 30192475

Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Policy Changes and Fiscal Year 2019 Rates; Quality Reporting Requirements for Specific Providers; Medicare and Medicaid Electronic Health Record (EHR) Incentive Programs (Promoting Interoperability Programs) Requirements for Eligible Hospitals, Critical Access Hospitals, and Eligible Professionals; Medicare Cost Reporting Requirements; and Physician Certification and Recertification of Claims. Final rule.

.   

Abstract

We are revising the Medicare hospital inpatient prospective payment systems (IPPS) for operating and capital-related costs of acute care hospitals to implement changes arising from our continuing experience with these systems for FY 2019. Some of these changes implement certain statutory provisions contained in the 21st Century Cures Act and the Bipartisan Budget Act of 2018, and other legislation. We also are making changes relating to Medicare graduate medical education (GME) affiliation agreements for new urban teaching hospitals. In addition, we are providing the market basket update that will apply to the rate-of-increase limits for certain hospitals excluded from the IPPS that are paid on a reasonable cost basis, subject to these limits for FY 2019. We are updating the payment policies and the annual payment rates for the Medicare prospective payment system (PPS) for inpatient hospital services provided by long-term care hospitals (LTCHs) for FY 2019. In addition, we are establishing new requirements or revising existing requirements for quality reporting by specific Medicare providers (acute care hospitals, PPS-exempt cancer hospitals, and LTCHs). We also are establishing new requirements or revising existing requirements for eligible professionals (EPs), eligible hospitals, and critical access hospitals (CAHs) participating in the Medicare and Medicaid Electronic Health Record (EHR) Incentive Programs (now referred to as the Promoting Interoperability Programs). In addition, we are finalizing modifications to the requirements that apply to States operating Medicaid Promoting Interoperability Programs. We are updating policies for the Hospital Value-Based Purchasing (VBP) Program, the Hospital Readmissions Reduction Program, and the Hospital-Acquired Condition (HAC) Reduction Program. We also are making changes relating to the required supporting documentation for an acceptable Medicare cost report submission and the supporting information for physician certification and recertification of claims.

Entities:  

Mesh:

Year:  2018        PMID: 30192475

Source DB:  PubMed          Journal:  Fed Regist        ISSN: 0097-6326


  21 in total

Review 1.  Addressing the Value of Gene Therapy and Enhancing Patient Access to Transformative Treatments.

Authors:  Rachel Salzman; Francesca Cook; Timothy Hunt; Harry L Malech; Philip Reilly; Betsy Foss-Campbell; David Barrett
Journal:  Mol Ther       Date:  2018-10-30       Impact factor: 11.454

2.  Changes in coding of pneumonia and impact on the Hospital Readmission Reduction Program.

Authors:  Jason D Buxbaum; Peter K Lindenauer; Colin R Cooke; Ushapoorna Nuliyalu; Andrew M Ryan
Journal:  Health Serv Res       Date:  2019-10-10       Impact factor: 3.402

3.  Early experiences with patient generated health data: health system and patient perspectives.

Authors:  Julia Adler-Milstein; Paige Nong
Journal:  J Am Med Inform Assoc       Date:  2019-10-01       Impact factor: 4.497

4.  Federal Bills Raise Cap on Medicare-Funded Residency Positions and Modify Graduate Medical Education Policies.

Authors:  Kristin Schleiter; Lauren Johnson
Journal:  J Grad Med Educ       Date:  2021-08-13

5.  Technology-facilitated care coordination in rural areas: What is needed?

Authors:  Emily Gill; Patricia C Dykes; Robert S Rudin; Marianne Storm; Kelly McGrath; David W Bates
Journal:  Int J Med Inform       Date:  2020-02-19       Impact factor: 4.046

6.  Cost comparison of andexanet versus prothrombin complex concentrates for direct factor Xa inhibitor reversal after hemorrhage.

Authors:  Jennifer A Frontera; Prachi Bhatt; Rebecca Lalchan; Shadi Yaghi; Tania Ahuja; John Papadopoulos; Danielle Joset
Journal:  J Thromb Thrombolysis       Date:  2020-01       Impact factor: 2.300

7.  Analysis of Price Transparency for Oncologic Surgery Among National Cancer Institute-Designated Cancer Centers in 2020.

Authors:  Roy Xiao; Lauren E Miller; Alan D Workman; Ryan A Bartholomew; Lucy J Xu; Vinay K Rathi
Journal:  JAMA Surg       Date:  2021-04-14       Impact factor: 14.766

8.  Survey of Hospital Chargemaster Transparency.

Authors:  Simone Arvisais-Anhalt; Samuel McDonald; Jason Y Park; Kandice Kapinos; Christoph U Lehmann; Mujeeb Basit
Journal:  Appl Clin Inform       Date:  2021-05-05       Impact factor: 2.342

9.  Economic Burden of Neurologic Toxicities Associated with Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States.

Authors:  Michael S Broder; Qiufei Ma; Tingjian Yan; Jie Zhang; Eunice Chang; David Kuzan; Lamis Eldjerou
Journal:  Am Health Drug Benefits       Date:  2020 Oct-Nov

10.  There is no market for new antibiotics: this allows an open approach to research and development.

Authors:  Dana M Klug; Fahima I M Idiris; Mark A T Blaskovich; Frank von Delft; Christopher G Dowson; Claas Kirchhelle; Adam P Roberts; Andrew C Singer; Matthew H Todd
Journal:  Wellcome Open Res       Date:  2021-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.